Recent technological advances have revealed considerable heterogeneity in the mutational profiles of tumours. A fundamental challenge is to translate these genomic discoveries into effective, personalized treatments for patients. One promising approach is to harness the power and exquisite specificity of each patient’s own immune system.
I am studying the immune response to lymphoma and myeloma with the goal of designing and conducting clinical trials of innovative immune-based therapies for lymphoid cancer patients at our centre. I am currently recruiting patients and cancer-free controls to participate in this research program.